Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Shareholder Meeting (November 2018)
27 slides from Prescient Therapeutics's shareholder meeting presentation, Nov 20, 2018
Slide 1: AGM Overview 2018
For personal use only AGM OVERVIEW 2018 Prescient Therapeutics Limited (ASX: PTX) 20 November 2018
Slide 2: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts b
Slide 3: Deep, Clinical Stage Product Pipeline
DEEP, CLINICAL STAGE PRODUCT PIPELINE • PTX-200 currently in three clinical trials For personal use only • Advancing PTX-100 in basket studies of Ras and Rho mutant cancers - a transformative opportunity DISCOVERY SCREENING PRE-CLINICAL PHASE 1 PHASE 1B PHASE 2 PHASE 3 PTX-200 BREAST CANCER PTX-200
Slide 4: Why Is Precision Medicine Changing the Industry?
WHY IS For personal use only PRECISION MEDICINE CHANGING THE INDUSTRY? 4 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 5: People Aren't the Same... Nor Are Tumours
PEOPLE AREN’T THE SAME…NOR ARE TUMOURS For personal use only • Treatment takes into account individual tumor variability • Doctors predict more accurately which anti-cancer drug will work in which groups of people • Not a one-size-fits-all approach where treatment is for all patients, with no attent
Slide 6: Benefits vs Standard Treatments
BENEFITS VS STANDARD TREATMENTS For personal use only This precise, targeted personalized therapy is a more effective way of treating cancer patients. 6 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 7: Examples of Precision Medicine Approaches
EXAMPLES OF PRECISION MEDICINE APPROACHES Disease Target Drug Status For personal use only Chronic Myeloid Bcr-Abl Gleevec has increased 5-year survival rate Gleevec for CML from 31% to 90% (1990s-2012) Leukemia (95% of patients) Acute Myeloid FLT3 Gilteritinib NDA filed for R/R FLT3-positive AML Le
Slide 8: PTX-200
PTX-200 For personal use only FIRST IN CLASS PH DOMAIN INHIBITOR WITH NOVEL AKT INHIBITION Breast cancer AML Ovarian cancer 8 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 9: From Roche at ASCO 2018: AKT Inhibitors Help Kill Breast Cancer Cells
FROM ROCHE AT ASCO 2018 : AKT INHIBITORS HELP KILL BREAST CANCER CELLS… For personal use only THE PI3K/AKT SURVIVAL PATHWAY IS ACTIVATED IN RESPONSE <BR />TO CHEMOTHERAPY 9 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE Presented By Rebecca Dent at 2018 ASCO Annual Meeting
Slide 10: ...And That Leads to Clinical Benefit
…AND THAT LEADS TO CLINICAL BENEFIT For personal use only 10 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE Presented By Rebecca Dent at 2018 ASCO Annual Meeting
Slide 11: PTX-200: Novel PH Domain Inhibition to Inactive AKT
PTX-200: NOVEL PH DOMAIN INHIBITION TO INACTIVE AKT For personal use only • PTX-200 binds to PH domains to inactivate, inter alia, Akt. » Mimics the phosphate of the natural ligand for the PH domain, PIP3 » By binding to the PH domain, PTX-200 prevents binding to the plasma membrane, thus inhibiting
Slide 12: HER2- Breast Cancer Overview
HER2 - BREAST CANCER OVERVIEW For personal use only 80% OF BREAST CANCERS ARE HER2- BUT THIS IS STILL UNDERSERVED BY NEW DRUGS $10.6B MARKET NEED: $5.4B LACK OF PIPELINE AGENTS ADDRESSING » RESISTANT ER+ DISEASE » NEOADJUVANT THERAPY 41% Generics 2015 2025 PTX’S NICHE: NEOADJUVANT » AKT IS ADVERSE P
Slide 13: What Does Success Look Like for This Disease?
WHAT DOES SUCCESS LOOK LIKE FOR THIS DISEASE? For personal use only • Studies on all sub-types of locally advanced breast cancer receiving weekly chemo reports a wide range of pCR (8-28%) • For women with locally advanced ER+, HER2 negative breast cancer, typical expectations are: » pCR of 16% (11-2
Slide 14: PTX-200 Breast Cancer Now in Phase 2a
PTX-200 BREAST CANCER NOW IN PHASE 2A For personal use only • PTX-200 35 mg/m2 in combination with paclitaxel, followed by AC (doxorubicin & cyclophosphamide) for neoadjuvant therapy • Patients with locally advanced HER2- breast cancer Joseph Sparano, M.D. Principal Investigator • 5 patients from Ph
Slide 15: Phase 1b Efficacy Results Very Encouraging
PHASE 1B EFFICACY RESULTS VERY ENCOURAGING For personal use only Metastatic & locally advanced patients Locally advanced patients ER+ Triple Total ER+ Triple Total negative negative pCR/CR 2 0 2 pCR/CR 2 0 2 PR 1 2 3 PR 1 2 3 SD 1 2 3 SD 0 0 0 PD 0 2 2 PD 0 0 0 ORR 75% 33% 50% ORR 100% Visual repres
Slide 16: Phase 1b Acute Myeloid Leukemia Trial
PHASE 1B ACUTE MYELOID LEUKEMIA TRIAL For personal use only • Phase 1 results with PTX-200 (monotherapy) very encouraging • Now PTX-200 + cytarabine in refractory or relapsed acute leukemia • Professor Jeff Lancet at Moffitt Cancer Center leading the trial Jeffrey E Lancet, M.D. • Yale Cancer Center
Slide 17: Phase 1b Ovarian Cancer Trial
PHASE 1B OVARIAN CANCER TRIAL For personal use only • Significant need for new products to treat platinum-resistant ovarian cancer • High pAkt contributes to platinum resistance • PTX-200 already proven overcome cisplatin resistance and synergize with cisplatin in pre-clinical studies Robert Wenham,
Slide 18: PTX-100
PTX-100 For personal use only PHASE 1 IN SOLID TUMORS COMPLETED NOW PURSUING A TRANSFORMATIVE OPPORTUNITY IN RAS & RHO MUTANT CANCERS 18 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 19: RhoA Mutations Play a Prominent Role in AITL Pathogenesis
RHOA MUTATIONS PLAY A PROMINENT ROLE IN AITL PATHOGENESIS For personal use only Schematic of RhoA protein structure, with alterations • RhoA G17V mutation is a driver of pathogenesis of AITL, PTCL-NOS • Other RhoA mutations driver a number of other malignancies • PTX-100 a pan RhoA inhibitor regardl
Slide 20: PTX-100 The Only Drug Targeting RhoA
PTX-100 THE ONLY DRUG TARGETING RHOA For personal use only • PTX-100 has a unique position in RhoA mutant malignancies • Only clinical stage RhoA inhibitor globally • Phase 1 trial in solid tumours completed – Unmet clinical safety profile established need (AITL & other TCLs) • PK/PD study expected
Slide 21: Case Study – Loxo Oncology
CASE STUDY – LOXO ONCOLOGY (NASDAQ:LOXO) • Lead drug Larotrectnib: targeted therapy for cancers with TRK fusions For personal use only • An unmet need in small patient population (2,500-3,000 cases/year in US) • Granted orphan and breakthrough designation • Only 4 years from initiating Phase 1 2014
Slide 22: Another Year of Solid Progress
ANOTHER YEAR For personal use only OF SOLID PROGRESS 22 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 23: The Year in Review
THE YEAR IN REVIEW For personal use only • Completion of PTX-200 Phase 1b breast cancer trial » Reporting very encouraging early data – twice that expected of standard of care » Now in Phase 2 • PTX-200 Phase 1b trial in AML enrolment completed on schedule » 2 CRs » Expanded trial with lower chemo d
Slide 24: In the Next Months We Will Work Towards
IN THE NEXT 12 MONTHS WE WILL WORK TOWARDS: For personal use only • Initiating the PTX-100 PK/PD study • Completing Phase 2 (part1) of PTX-200 in breast cancer • Completing Phase 1b expanded cohort of PTX-200 in AML • Completing Phase 1b PTX-200 in ovarian cancer • Completing manufacturing run of PT
Slide 25: Where Are We?
WHERE ARE WE? For personal use only RISK VALUE SPEND TARGETED THERAPIES YIELDING A DEEP CLINICAL 25 PIPELINE
Slide 26: Investment Summary
INVESTMENT SUMMARY For personal use only A GREAT LAUNCH PAD FOR TRANSFORMATION • Underpinned by PTX-200 » Any one of 3 trials a potential company maker » Encouraging data already unfolding in breast cancer • Transformative opportunity on PTX-100 • Excellent team with successful track record • Overla
Slide 27: Thank you for your ongoing support
Thank you for your For personal use only ongoing support CONTACT Steven Yatomi-Clarke e: steven@ptxtherapeutics.com CEO & Managing Director t: +61 417 601 440 Prescient Therapeutics Limited w: ptxtherapeutics.com
Prescient Therapeutics — Shareholder Meeting (November 2018) on 6ix